CRISPR Therapeutics AG Quarterly Net Cash Provided by (Used in) Financing Activities in USD from Q1 2018 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
CRISPR Therapeutics AG quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from Q1 2018 to Q1 2024.
  • CRISPR Therapeutics AG Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2024 was $306M, a 5561% increase year-over-year.
  • CRISPR Therapeutics AG annual Net Cash Provided by (Used in) Financing Activities for 2023 was $62.7M, a 62.4% increase from 2022.
  • CRISPR Therapeutics AG annual Net Cash Provided by (Used in) Financing Activities for 2022 was $38.6M, a 84.6% decline from 2021.
  • CRISPR Therapeutics AG annual Net Cash Provided by (Used in) Financing Activities for 2021 was $251M, a 75.3% decline from 2020.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $306M +$301M +5561% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q1 2023 $5.4M -$5.25M -49.3% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q1 2022 $10.6M -$215M -95.3% Jan 1, 2022 Mar 31, 2022 10-Q 2022-05-09
Q1 2021 $226M +$225M +19864% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q1 2020 $1.13M -$24.6M -95.6% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-27
Q1 2019 $25.7M -$99.5M -79.5% Jan 1, 2019 Mar 31, 2019 10-Q 2020-04-28
Q1 2018 $125M Jan 1, 2018 Mar 31, 2018 10-Q 2019-04-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.